The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations

American Journal of Gastroenterology

Volumn 107, Issue 5, 2012, Pages 736-746

  Martínez, Cristina ^a   Vicario, María ^a,b   Ramos, Laura ^a   Lobo, Beatriz ^a   Mosquera, Jose Luis ^a   Alonso, Carmen ^a   Sánchez, Alex ^a,c   Guilarte, Mar ^a,d   Antolín, María ^a,b   De Torres, Inés ^d   González Castro, Ana M ^a   Pigrau, Marc ^a   Saperas, Esteban ^a   Azpiroz, Fernando ^a,b   Santos, Javier ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ZO1;

ADULT; ARTICLE; CELL ACTIVATION; CELL COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DIARRHEA; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; JEJUNUM BIOPSY; JEJUNUM MUCOSA; LYMPHOCYTE; MALE; MAST CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; GENETICS; INTESTINE MUCOSA; JEJUNUM; METABOLISM; MIDDLE AGED; PATHOLOGY; PERMEABILITY;

ADULT; DIARRHEA; FEMALE; GENE EXPRESSION; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; JEJUNUM; LYMPHOCYTES; MALE; MAST CELLS; MICROARRAY ANALYSIS; MIDDLE AGED; PERMEABILITY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; YOUNG ADULT;

EID: 84862336762     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.472     Document Type: Article

References (43)

1. Faresjo A, Grodzinsky E, Johansson S et al. Psychosocial factors at work and in every day life are associated with irritable bowel syndrome. Eur J Epidemiol 2007;22:473-80. (Pubitemid 47222952)
2. Bennet EJ, Tennant CC, Piesse C et al. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998;43:256-61. (Pubitemid 28348331)
3. Nicholl BI, Halder SL, Macfarlane GJ et al. Psychosocial risk markers for new onset irritable bowel syndrome-results of a large prospective population-based study. Pain 2008;137:147-55. (Pubitemid 351794403)
4. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-88.
5. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. (Pubitemid 43829995)
6. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146:41-6.
7. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
8. Marshall JK, Thabane M, Garg AX et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004;20:1317-22. (Pubitemid 40040078)
9. Piche T, Barbara G, Aubert P et al. Impaired intestinal integrity in the colon of irritable bowel syndrome patients: involvement of soluble mediators. Gut 2009;58:196-201.
10. Coeffier M, Gloro R, Boukhettala N et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010;105:1181-8.
11. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9:799-809.
12. Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell 2010;140:859-70.
13. Alonso C, Guilarte M, Vicario M et al. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology 2008;135:163-72.
14. Soderholm JD, Yang PC, Ceponis P et al. Chronic stress induces mast cell dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002;123:1099-108.
15. Qiu BS, Vallance BA, Blennerhassett PA et al. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med 1999;5:1178-82. (Pubitemid 29474423)
16. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-47. (Pubitemid 46348522)
17. Klooker TK, Braak B, Koopman KE et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213-21.
18. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523-6. (Pubitemid 36363405)
19. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83. (Pubitemid 34651421)
20. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. (Pubitemid 38298317)
21. Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203-9.
22. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73.
23. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37. (Pubitemid 46108761)
24. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425-34.
25. Aerssens J, Camilleri M, Talloen W et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:194-205. (Pubitemid 351172944)
26. Macsharry J, O'Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008;43:1467-76.
27. Talley NJ, Stanghellini V, Heading RC et al. Functional gastroduodenal disorders. Gut 1999;45:1137-42.
28. Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Med 1967;11:213-8.
29. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4. (Pubitemid 27382038)
30. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101-8. (Pubitemid 351818697)
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc B 1995;85:289-300.
32. Guillemot L, Paschoud S, Pulimeno P et al. The cytoplasmic plaque of tight junctions: a scaffolding and signalling center. Biochim Biophys Acta 2008;1778:601-13.
33. Gecse K, Róka R, Ferrier L et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008;57:591-9.
34. Utech M, Mennigen R, Bruewer M. Endocytosis and recycling of tight junction proteins in inflammation. J Biomed Biotechnol 2010;2010:484987.
35. Hopkins AM, Walsh SV, Verkade P et al. Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. J Cell Sci 2003;116 (Part 4):725-42. (Pubitemid 36231311)
36. Marchiando AM, Shen L, Graham WV et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 2010;189:111-26.
37. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008;8:478-86. (Pubitemid 351733419)
38. Aichberger KJ, Mayerhofer M, Gleixner KV et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007;109:3031-41. (Pubitemid 46482104)
39. Möller C, Alfredsson J, Engström M et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005;106:1330-6. (Pubitemid 41129597)
40. Berent-Maoz B, Piliponsky AM, Daigle I et al. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 2006;176:2272-8. (Pubitemid 43201674)
41. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392-400.
42. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005;34:235-45. (Pubitemid 40615953)
43. Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 2006;19:1638-45. (Pubitemid 44789933)